Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Sep;72(3):757–765. doi: 10.1038/bjc.1995.406

Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study.

J H Youngson 1, J M Jones 1, J G Chang 1, M Harris 1, S S Banergee 1
PMCID: PMC2033900  PMID: 7669590

Abstract

Classification of lymphoid malignancy has changed markedly in recent years and advances have been made in therapy. This study investigated the variations in treatment and survival of 1622 patients in a population-based registry. A total of 1009 cases of malignant lymphoma (ML) were classified according to the Kiel classification. Pathology review resulted in major diagnostic changes for 24% of cases. Of the ML cases, 39% had not had full staging procedures. Younger patients were more likely to have been treated with multiagent chemotherapy regimens, as were patients with B symptoms. Median survival for ML patients was 12 months for high-grade patients and more than 60 months for low-grade patients. Significant factors affecting the survival of ML patients were performance status, whether treatment had followed a recognised protocol, whether treatment had been carried out at a specialist oncology centre (SOC), grade of disease, stage, gender and age. The same factors had a significant effect on survival of the leukaemia patients, except for treatment at an SOC, which had a significant favourable effect on survival of acute lymphoblastic leukaemia (ALL) patients only. Median survival for patients with chronic lymphocytic leukaemia was 43 months and 7 months for ALL patients.

Full text

PDF
757

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BERKSON J., GAGE R. P. Calculation of survival rates for cancer. Proc Staff Meet Mayo Clin. 1950 May 24;25(11):270–286. [PubMed] [Google Scholar]
  2. Barnett M. J., Greaves M. F., Amess J. A., Gregory W. M., Rohatiner A. Z., Dhaliwal H. S., Slevin M. L., Biruls R., Malpas J. S., Lister T. A. Treatment of acute lymphoblastic leukaemia in adults. Br J Haematol. 1986 Nov;64(3):455–468. doi: 10.1111/j.1365-2141.1986.tb02201.x. [DOI] [PubMed] [Google Scholar]
  3. Bartl R., Hansmann M. L., Frisch B., Burkhardt R. Comparative histology of malignant lymphomas in lymph node and bone marrow. Br J Haematol. 1988 Jun;69(2):229–237. doi: 10.1111/j.1365-2141.1988.tb07627.x. [DOI] [PubMed] [Google Scholar]
  4. Benn R. T., Leck I., Nwene U. P. Estimation of completeness of cancer registration. Int J Epidemiol. 1982 Dec;11(4):362–367. doi: 10.1093/ije/11.4.362. [DOI] [PubMed] [Google Scholar]
  5. Bird C. C., Lauder I., Kellett H. S., Chorlton I., Barnes N., Darwin C., Cartwright R. A., Boyko R. Yorkshire Regional Lymphoma Histopathology panel: analysis of five years' experience. J Pathol. 1984 Aug;143(4):249–258. doi: 10.1002/path.1711430404. [DOI] [PubMed] [Google Scholar]
  6. Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971 Nov;31(11):1860–1861. [PubMed] [Google Scholar]
  7. Cowan R. A., Jones M., Harris M., Steward W. P., Radford J. A., Wagstaff J., Deakin D. P., Crowther D. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. Br J Cancer. 1989 Feb;59(2):276–282. doi: 10.1038/bjc.1989.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dick F. R., VanLier S. F., McKeen K., Everett G. D., Blair A. Nonconcurrence in abstracted diagnoses of non-Hodgkin's lymphoma. J Natl Cancer Inst. 1987 Apr;78(4):675–678. [PubMed] [Google Scholar]
  9. Dick F., VanLier S., Banks P., Frizzera G., Witrak G., Gibson R., Everett G., Schuman L., Isacson P., O'Conor G. Use of the working formulation for non-Hodgkin's lymphoma in epidemiologic studies: agreement between reported diagnoses and a panel of experienced pathologists. J Natl Cancer Inst. 1987 Jun;78(6):1137–1144. [PubMed] [Google Scholar]
  10. Ersbøll J., Schultz H. B., Hougaard P., Nissen N. I., Hou-Jensen K. Comparison of the working formulation of non-Hodgkin's lymphoma with the Rappaport, Kiel, and Lukes & Collins classifications. Translational value and prognostic significance based on review of 658 patients treated at a single institution. Cancer. 1985 May 15;55(10):2442–2458. doi: 10.1002/1097-0142(19850515)55:10<2442::aid-cncr2820551024>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  11. Feigl P., Glaefke G., Ford L., Diehr P., Chu J. Studying patterns of cancer care: how useful is the medical record? Am J Public Health. 1988 May;78(5):526–533. doi: 10.2105/ajph.78.5.526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fentiman I. S., Tirelli U., Monfardini S., Schneider M., Festen J., Cognetti F., Aapro M. S. Cancer in the elderly: why so badly treated? Lancet. 1990 Apr 28;335(8696):1020–1022. doi: 10.1016/0140-6736(90)91075-l. [DOI] [PubMed] [Google Scholar]
  13. Fentiman I. S. Treatment of cancer in the elderly. Br J Cancer. 1991 Dec;64(6):993–995. doi: 10.1038/bjc.1991.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Karjalainen S., Palva I. Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland. BMJ. 1989 Oct 28;299(6707):1069–1072. doi: 10.1136/bmj.299.6707.1069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kim H., Zelman R. J., Fox M. A., Bennett J. M., Berard C. W., Butler J. J., Byrne G. E., Jr, Dorfman R. F., Hartsock R. J., Lukes R. J. Pathology Panel for Lymphoma Clinical Studies: a comprehensive analysis of cases accumulated since its inception. J Natl Cancer Inst. 1982 Jan;68(1):43–67. [PubMed] [Google Scholar]
  16. Marcus R. E., Catovsky D., Johnson S. A., Gregory W. M., Talavera J. G., Goldman J. M., Galton D. A. Adult acute lymphoblastic leukaemia: a study of prognostic features and response to treatment over a ten year period. Br J Cancer. 1986 Feb;53(2):175–180. doi: 10.1038/bjc.1986.32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. McIllmurray M. B. District cancer physicians. Report of a Working Group of the Association of Cancer Physicians. J R Coll Physicians Lond. 1987 Apr;21(2):117–121. [PMC free article] [PubMed] [Google Scholar]
  18. Mead G. M. Malignant lymphoma--a clinician's view. J Pathol. 1987 Mar;151(3):179–182. doi: 10.1002/path.1711510303. [DOI] [PubMed] [Google Scholar]
  19. Monfardini S., Chabner B. Joint NCI-EORTC consensus meeting on neoplasia in the elderly. San Servolo Island, Venice, 15-16 October 1990. Eur J Cancer. 1991;27(5):653–654. doi: 10.1016/0277-5379(91)90237-8. [DOI] [PubMed] [Google Scholar]
  20. O'Reilly S. E., Connors J. M. Non-Hodgkin's lymphoma. I: Characterisation and treatment. BMJ. 1992 Jun 27;304(6843):1682–1686. doi: 10.1136/bmj.304.6843.1682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. O'Reilly S. E., Connors J. M. Non-Hodgkin's lymphoma. II: Management problems. BMJ. 1992 Jul 4;305(6844):39–42. doi: 10.1136/bmj.305.6844.39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Oliver R. T. Rare cancers and specialist centres. Br Med J (Clin Res Ed) 1986 Mar 8;292(6521):641–642. doi: 10.1136/bmj.292.6521.641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rosenberg S. A. Hodgkin's disease: no stage beyond cure. Hosp Pract (Off Ed) 1986 Aug 15;21(8):91-8, 101-8. [PubMed] [Google Scholar]
  24. Simon R., Durrleman S., Hoppe R. T., Bonadonna G., Bloomfield C. D., Rudders R. A., Cheson B. D., Berard C. W. The Non-Hodgkin Lymphoma Pathologic Classification Project. Long-term follow-up of 1153 patients with non-Hodgkin lymphomas. Ann Intern Med. 1988 Dec 15;109(12):939–945. doi: 10.7326/0003-4819-109-12-939. [DOI] [PubMed] [Google Scholar]
  25. Somers R., Burgers J. M., Qasim M., Van Glabbeke M., Duez N., Hayat M. EORTC trial non-Hodgkin lymphomas. Eur J Cancer Clin Oncol. 1987 Mar;23(3):283–293. doi: 10.1016/0277-5379(87)90072-1. [DOI] [PubMed] [Google Scholar]
  26. Stiller C. A. Survival of patients with cancer. BMJ. 1989 Oct 28;299(6707):1058–1059. doi: 10.1136/bmj.299.6707.1058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Swerdlow A. J., Douglas A. J., Vaughan Hudson G., Vaughan Hudson B. Completeness of cancer registration in England and Wales: an assessment based on 2,145 patients with Hodgkin's disease independently registered by the British National Lymphoma Investigation. Br J Cancer. 1993 Feb;67(2):326–329. doi: 10.1038/bjc.1993.60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Taylor P. R., Reid M. M., Bown N., Hamilton P. J., Proctor S. J. Acute lymphoblastic leukemia in patients aged 60 years and over: a population-based study of incidence and outcome. Blood. 1992 Oct 1;80(7):1813–1817. [PubMed] [Google Scholar]
  29. Tirelli U., Zagonel V., Serraino D., Thomas J., Hoerni B., Tangury A., Ruhl U., Bey P., Tubiana N., Breed W. P. Non-Hodgkin's lymphomas in 137 patients aged 70 years or older: a retrospective European Organization for Research and Treatment of Cancer Lymphoma Group Study. J Clin Oncol. 1988 Nov;6(11):1708–1713. doi: 10.1200/JCO.1988.6.11.1708. [DOI] [PubMed] [Google Scholar]
  30. Vose J. M., Armitage J. O., Weisenburger D. D., Bierman P. J., Sorensen S., Hutchins M., Moravec D. F., Howe D., Dowling M. D., Mailliard J. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1988 Dec;6(12):1838–1844. doi: 10.1200/JCO.1988.6.12.1838. [DOI] [PubMed] [Google Scholar]
  31. Wolf B. C., Gilchrist K. W., Mann R. B., Neiman R. S. Evaluation of pathology review of malignant lymphomas and Hodgkin's disease in cooperative clinical trials. The Eastern Cooperative Oncology Group experience. Cancer. 1988 Oct 1;62(7):1301–1305. doi: 10.1002/1097-0142(19881001)62:7<1301::aid-cncr2820620710>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES